PA
CSTL icon

Parallel Advisors’s Castle Biosciences CSTL Stock Holding History

Parallel Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$308K Sell
12,931
-370
-3% -$8.24K ﹤0.01% 1010
2026
Q1 		$327K Sell
13,301
-685
-5% -$22.4K 0.01% 909
2025
Q4 		$544K Sell
13,986
-3,800
-21% -$123K 0.01% 653
2025
Q3 		$405K Sell
17,786
-10,107
-36% -$205K 0.01% 747
2025
Q2 		$570K Buy
27,893
+300
+1% +$5.55K 0.01% 585
2025
Q1 		$551K Sell
27,593
-402
-1% -$9.95K 0.01% 556
2024
Q4 		$746K Buy
27,995
+3
+0% +$91 0.02% 470
2024
Q3 		$798K Buy
27,992
+1,524
+6% +$38.8K 0.02% 435
2024
Q2 		$576K Sell
26,468
-200
-0.7% -$4.46K 0.01% 495
2024
Q1 		$591K Sell
26,668
-300
-1% -$6.53K 0.02% 483
2023
Q4 		$582K Hold
26,968
– – 0.02% 449
2023
Q3 		$455K Sell
26,968
-87
-0.3% -$1.52K 0.02% 482
2023
Q2 		$371K Buy
27,055
+4,986
+23% +$101K 0.01% 558
2023
Q1 		$501K Hold
22,069
– – 0.02% 464
2022
Q4 		$520K Sell
22,069
-22
-0.1% -$510 0.02% 395
2022
Q3 		$576K Hold
22,091
– – 0.03% 357
2022
Q2 		$485K Buy
22,091
+182
+0.8% +$4.23K 0.02% 403
2022
Q1 		$964K Buy
21,909
+140
+0.6% +$5.79K 0.04% 274
2021
Q4 		$933K Hold
21,769
– – 0.03% 284
2021
Q3 		$1.45M Sell
21,769
-22
-0.1% -$1.55K 0.06% 202
2021
Q2 		$1.6M Buy
21,791
+1,791
+9% +$118K 0.07% 191
2021
Q1 		$1.37M Sell
20,000
-5,000
-20% -$376K 0.06% 191
2020
Q4 		$1.68M Sell
25,000
-14,420
-37% -$782K 0.09% 156
2020
Q3 		$2.03M Buy
39,420
+19,420
+97% +$864K 0.13% 133
2020
Q2 		$753K Buy
+20,000
New +$683K 0.05% 220

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Parallel Advisors's CSTL Position: Q2 2026 in Review

Parallel Advisors reduced its Castle Biosciences (CSTL) stake by 2.8% in Q2 2026, selling an estimated $8.24K and leaving 12,931 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #1010.

Parallel Advisors first reported a position in CSTL in Q2 2020 and has held it in 25 quarters since. The position peaked at $2.03M in Q3 2020. 61 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Parallel Advisors held 12,931 shares of Castle Biosciences worth $308K as of Q2 2026.
  • Parallel Advisors sold 370 Castle Biosciences shares in Q2 2026, an estimated $8.24K.
  • Castle Biosciences made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #1010 holding.
  • Parallel Advisors first reported a position in Castle Biosciences in Q2 2020 and has held it in 25 quarters since.
  • Parallel Advisors's Castle Biosciences position peaked at $2.03M in Q3 2020.
  • 61 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.